The Food and Drug Administration advisers voted 7-2 that data from Amylyx Pharma warranted approval, despite ongoing concerns about the strength and reliability of the company’s study. The vote is not binding a
A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to.